Seena K. X., M. Manjunath Setty
Seena K. X1., M. Manjunath Setty2*
1Department of Pharmacognosy, KMP College of Pharmacy, Perumbavoor.
2Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Volume - 14,
Issue - 7,
Year - 2021
Cisplatin is an inorganic platinum-based oncologic medication and has a broad spectrum of uses in the therapeutic management of number of solid malignant tumour. FDA approved the clinical use of cisplatin in the year 1978. Since then, it has been used alone or in combination with other drugs in chemotherapy. Though, it has highly cured rate for the treatment of cancer, the use of cisplatin is limited due to its major dose limiting side effects such as nephrotoxicity and ototoxicity. The development of cisplatin nephrotoxicity is complex and a number of interrelated factors such as transporter mediated cisplatin accumulation, conversion into nephrotoxins, formation of DNA adducts, mitochondrial dysfunction, nitrosative and oxidative stress, inflammation, signal transducers and apoptotic pathway activation are involved. A number of synthetic drugs are available for the management of cisplatin toxicity but associated with a number of serious side effects such as hypotension, ototoxicity, nausea, vomiting and decreased calcium levels. In addition, various reports show that most of these compounds show unwanted tumour protective activity. Literature review suggested that phytochemicals are reported to have preventive activity in CIRT and it is evident that these compounds showed a pronounced renoprotective activity against CIRT. Therefore, in this review, we highlight the role of the phytochemicals, which are shown to be efficacious in clinically.
Cite this article:
Seena K. X., M. Manjunath Setty. Protective effect of Phytochemicals against Cisplatin induced Nephrotoxicity. Research Journal of Pharmacy and Technology. 2021; 14(7):3981-6. doi: 10.52711/0974-360X.2021.00690
Seena K. X., M. Manjunath Setty. Protective effect of Phytochemicals against Cisplatin induced Nephrotoxicity. Research Journal of Pharmacy and Technology. 2021; 14(7):3981-6. doi: 10.52711/0974-360X.2021.00690 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-7-87
1. Neife, A. G. S., Maria, A. C. R., Nadia, M. M. and Antonio, C. S, Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Archives Toxicology. 2012; 86: 1233– 1250.
2. Shalom Desari and Paul BT. Cisplatin in cancer therapy: Molecular mechanisms of action. European journal of pharmacology. 2014; 740: 364-378.
3. Lin L, Jing Z, Weiping Z, Ning, J. Nephroprotective Effect of Gelsemine Against Cisplatin-Induced Toxicity is mediated via Attenuation of Oxidative Stress. Cell Biochemistry and Biophysics. 2015; 71: 535–541.
4. Hanigan M. H, Lykissa E.D and Townsend D. M, Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. American Journal of Pathology.2001; 159:1889–1894.
5. Ciarimboli, G, Deuster D, Kneif A, Sperling M et al, Organic cation transporters 2 mediates cisplatin induced ototoxicity and nephrotoxicity and is a target for preventive interventions. American Journal of Pathology. 2010; 176: 1169-1180.
6. Ludwig T, Riethmuller C and Gekle M. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney International. 2004; 66: 196–202.
7. Ishida S., Lee, J, Thiele D.J. and Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:14298–14302
8. Hausheer F. H., Parker, A. R., Petluru P, Jair N. K et al, Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N. Cancer Chemotherapy and Pharmacology. 2011; 67: 381–391.
9. Vladislav V, Bojana D, Marina G.J, et al, Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. Journal of Biomedical Sciences. 2019; 25: 1-14.
10. Hayati F, Hossainzadeh M, Shayanpour S, Abedi-Gheshlaghi Z, Beladi Mousavi SS. Prevention of cisplatin nephrotoxicity. Journal of Nephropharmacology 2015; 25(1):57-60.
11. Lee, R. H., Song, J. M., Park, M. Y., Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochemical Pharmacology. 2001; 62: 1013–1023.
12. Cilenti L, Kyriazis G A, Soundarapandian M M etal, Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. American journal of Physiology- Renal Physiology. 2005; 288: F371–F379.
13. Jiang M, Wei Q, Wang j et al, Regulation of PUMA-alpha by p53in cisplatin induced renal cell apoptosis. oncogenes, 2006; 29; 405-666.
14. Navajotsingh and Zheng Dang. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney international. 2008; 73(9): 994-1007.
15. Kang KP, Park SK, Kim DH et al, Luteolin ameliorates cisplatin- induced acute kidney injury in mice by regulation of p53- dependant renal tubular apoptosis. Nephrology Dialysis Transplant. 2011; 26(3): 814-822.
16. Tsuruya K, Ninomiya T, Tokumoto M et al, Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney International. 2003; 63: 72–82.
17. Beyaert R. and Fiers W. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Letter. 1994; 340: 9–16.
18. Yang C, Kaushal V, Haun R et al, Transcriptional activation of caspase-6 and -7 genes by cisplatin induced p53 and its functional significance in cisplatin nephrotoxicity. Cell death and differentiation. 2008; 15: 530-544.
19. Hua Liu and Radhakrishna Baliga, Cytochrome P450 2E1 null mice provide novel protection against cisplatin -induced nephrotoxicity and apoptosis. Kidney international. 2003; 63: 1687-1696.
20. Salma M, Kapil S, Jagriti B et al, Molecular mechanisms underlying attenuation of cisplatin-induced acute kidney injury by epicatechin gallate. Laboratory investigation. 2016; 96: 853-861.
21. Yao X, Panichpisal K, Kurtzman N et al, Cisplatin nephrotoxicity: a review. American Journal of Medical Sciences. 2007; 334(2):115–24.
22. Francescato H D C, Coimbra T M, Costa R S et al, Protective effect of quercetin on the evolution of cisplatin induced acute tubular necrosis. Kidney Blood Pressure Research. 2004; 27:148-158.
23. Baliga, R., Zhang, Z., Baliga, M., Ueda, N. and Shah, S.V. 1998. “Role of cytochrome P450 as a source of catalytic iron in cisplatin induced nephrotoxicity. Kidney International. 54, 1562–1569.
24. Bidya D. S, Madhusudana K, Uday K. P. Effect of metformin against cisplatin induced acute renal injury in rats: A biochemical and histoarchitectural evaluation. Experimental and Toxicologic Pathology. 2016; 65: 930-944.
25. Luis, A. B P. and Ademar, D. C. J. Acute Nephrotoxicity of Cisplatin: Molecular mechanisms. Brazilian Journal of Nephrology.2012; 35: 332-340.
26. Hayati F, Hossainzadeh M, Shayanpour S, Abedi-Gheshlaghi Z, Beladi Mousavi SS. Prevention of cisplatin nephrotoxicity. Journal of Nephropharmacology. 2015; 5(1):57–60.
27. Hausheer FH, Shanmugarajah D, Leverett BD et al, Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemotherapy Pharmacology. 2010; 65(5):941-51.
28. Ruggiero A, Trombatore G, Triarico, S. Platinum compounds in children with cancer: toxicity and clinical management. Anti-Cancer Drug. 2013; 24: 1007–1019.
29. Penelope D. Sanchez-Gonzalez, Francisco J. Lopez-Hernandez et al, Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity, Nephrology Dialysis Transplantation. 2011; 26(11): 3484–3495.
30. Rimando AM, Kalt W, Magee JB, et al., “Resveratrol, pterostilbene, and piceatannol in Vaccinium berries,” Journal of Agricultural and Food Chemistry.2004; 52(15): 4713–4719.
31. Valentovic MA, Ball JG, Mike Brown J, et al. “Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress. Toxicology in Vitro; 28(4): 248–57.
32. Do Amaral CL, Francescato HDC, Coimbra TM et al., “Resveratrol attenuates cisplatin-induced nephrotoxicity in rats”. Archives of Toxicology. 2008; 82(6); 363–370.
33. Osman AMM, Telity SA, Damanhouri ZA et al., “Chemosensitizing and nephroprotective effect of resveratrol in cisplatin-treated animals,” Cancer Cell International. 2015; 15(6): 1-8.
34. Ueki M, Ueno M, Morishita J, Maekawa N. Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. Journal of Bioscience and Bioengineering. 2013; 115(5): 547–551.
35. Trujillo J, Chirino Y. I, Molina-Jijón E, Andérica-Romero A. C j, et al, Reno protective effect of the antioxidant curcumin: recent findings. Redox Biology. 2013; 1(1):448–456.
36. Ugur S, Ulu, Dogukan A, et al. The renoprotective effect of curcumin in cisplatin-induced nephrotoxicity. Renal Failure. 2015; 37(2):332–336.
37. Fernández-Rojas, Medina-Campos ON, Hernández-Pando, M, et al, “C-Phycocyanin prevents cisplatin-induced nephrotoxicity through inhibition of oxidative stress,” Food and Function 2014; 5(3) 480–490.
38. B. Horváth, P. Mukhopadhyay, M. Kechrid et al., “β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner,” Free Radical Biology and Medicine.2012; 52(8): 1325–1333.
39. K. Sahin, M. Tuzcu, N. Sahin, S. Ali, and O. Kucuk, “Nrf2/HO-1 signaling pathway may be the prime target for chemoprevention of cisplatin-induced nephrotoxicity by lycopene,” Food and Chemical Toxicology. 2010; 48(10): 2670–2674.
40. Sahin K., Tuzcu M., Gencoglu H., et al. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sciences. 2010; 87(7-8):240–245.
41. Chen B., Liu G., Zou P., et al. Epigallocatechin-3-gallate protects against cisplatin-induced nephrotoxicity by inhibiting endoplasmic reticulum stress-induced apoptosis. Experimental Biology and Medicine. 2015; 240(11):1513–1519.
42. Zou P., Song J., Jiang B., et al. Epigallocatechin-3-gallate protects against cisplatin nephrotoxicity by inhibiting the apoptosis in mouse. International Journal of Clinical and Experimental Pathology. 2014; 7(8):4607–4616.
43. Ahmad S. T., Sultana S. Tannic acid mitigates cisplatin-induced nephrotoxicity in mice. Human and Experimental Toxicology. 2012; 31(2):145–156.
44. Tikoo K., Bhatt D. K., Gaikwad A. B., Sharma V., Kabra D. G. Differential effects of tannic acid on cisplatin induced nephrotoxicity in rats. FEBS Letters. 2007; 581(10):2027–2035.
45. Guerrero-Beltrán C. E., Calderón-Oliver M., Tapia E., et al. Sulforaphane protects against cisplatin-induced nephrotoxicity. Toxicology Letters. 2010; 192(3):278–285.
46. Gaona-Gaona L., Molina-Jijón E., Tapia E., et al. Protective effect of sulforaphane pretreatment against cisplatin-induced liver and mitochondrial oxidant damage in rats. Toxicology. 2011; 286(1–3):20–27.
47. Hofmann A. S., Gross G. G. Biosynthesis of gallotannins: formation of polygalloyl glucoses by enzymatic acylation of 1, 2, 3, 4, 6-penta-O-galloylglucose. Archives of Biochemistry and Biophysics. 1990; 283(2):530–532.
48. Omitrović R, Cvijanović O, Pugel E. P, Zagorac G. B, ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology. 2013; 310:115–123.
49. Kang K. P., Park S. K., Kim D. H., et al. Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis. Nephrology Dialysis Transplantation. 2011; 26(3):814–822.
50. Sahu B. D, Rentam K. K. R, Putcha U. K, et al., Carnosic acid attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Food and Chemical Toxicology. 2011; 49(12):3090–3097.
51. Waly M. I, Ali B. H, Al-Lawati I, Nemmar A. Protective effects of emodin against cisplatin-induced oxidative stress in cultured human kidney (HEK 293) cells. Journal of Applied Toxicology. 2013; 33(7):626–630.
52. Ali B. H, Al-Salam S, Al Husseini I. S, et al. Abrogation of cisplatin-induced nephrotoxicity by emodin in rats. Fundamental and Clinical Pharmacology. 2013; 27(2):192–200.